網誌文章搜尋建議

給多發性硬化症MS病友和親友的建議:
如要搜尋站內相關文章可多利用
"搜尋此網誌的文章內容"的功能,這樣就可以快速的找到你想要得資訊而不需要從第一篇開始看了.
有關CCSVI(靜脈血管窄化及手術的資訊)可在相關連結以及相關MS blog內

推薦頻道:Gimmy a break

2012年3月22日 星期四

病毒, 免疫, 遺傳 還是血管? update

從有這個病至今至少也約半百年的歷史, 但是研究仍然如火如荼的進行著。原因依舊不明,就有如隨時發作的不確定感一般。公說公有理,婆說婆有理。只能夠看相信的人或者是取樣數據的比例如何。

EBV病毒引起多發性硬化症?

2011-01-13

  最新研究發現EBV病毒與多發性硬化症有關美國專家在近期研究中發現,誘發單核細胞增多症的非洲淋巴細胞瘤病毒(Epstein-Barrvirus,EBV會增加患多發性硬化症MS的危險。儘管以往都認為該病與自體免疫功能的異常有關,但相應的常規藥物對於MS患者卻往往無效。

  近來已有越來越多的證據表明病毒在MS的誘發中具有重要作用,這可能是因為病毒會直接攻擊神經系統或後者產生的抗體會轉而影響到神經系統自身。

  有關研究報告日前發表在《美國醫學會雜誌》上。哈佛公共衛生學院的流行病學專家AlbertoAscherio醫學博士等在該項研究中對六萬多份婦女捐獻的血樣進行了分析測定,其中有144例後來患了多發性硬化症。在與非MS患者的血樣進行比較後發現,她們的血樣中所含的抗EBV抗體量要明顯更高。

  有關專家因此而認為,雖然目前尚不清楚為什麼大多數EBV感染者最終並不會患多發性硬化症,但這卻證實了MS與EBV病毒感染確實是密切相關的。


Neurology:首次證實EBV病毒與多發性硬化症存在關聯 2012-1-11


兩個EBV病毒顆粒,圖片來自維基共享資源。

英國倫敦大學研究人員的一篇新研究表明一種特定病毒如何欺騙免疫系統促發炎症,並對大腦中神經細胞造成傷​​害,而這些已知能夠導致多發性硬化症(multiple sclerosis)。

以前的研究提示著愛潑斯坦-巴爾病毒(Epstein-Barr virus, EBV)與多發性硬化症存在關聯,但是它一直充滿爭議,因為科學家一直不能證實這種關聯。

這一新研究證實該病毒以一種比以前所想像的更加複雜和更加微妙的方式參與當中,可能提供新的方法來治療或阻止這種疾病。

多發性硬化症乃是中樞神經系統和免疫有關的發炎及去髓鞘疾病。實際上,神經軸突(axon)、神經元(neuron)及寡棘突細胞(oligodedrocyte)亦會受損。它的原因一直沒有完全理解,但是已知基因和環境都發揮著作用。

這篇新研究發表在《Neurology》期刊上,研究人員研究了多發性硬化症病人死後的大腦,檢查了神經傷害最近發生的地區。

該研究通信作者Ute-Christiane Meier博士解釋道,“EBV是受多發性硬化症影響的病人大腦中一種相當聰明的病毒,甚至是當它在細胞中隱藏自己的時候。”

Meier博士和她的合作人員小組發現,儘管該病毒並不主動地傳播,但是它釋放化學信息到附近的大腦區域。這些化學信息---是由小RNA分子組成的---激活身體的免疫系統,導致炎症。這傷害了大腦中神經細胞,導致多發性硬化症產生。

Meier博士繼續說道,“我們不得不謹慎小心,不得不研究更多的多發性硬化症大腦,不過這是一項潛在上非常有趣的研究。如今,我們理解EBV如何通過免疫系統細胞偷運到大腦中,在犯罪現場發現了它,就是在我們神經系統遭受攻擊的地方。如今,我們知道這點,我們可能有許多方法治療或甚至阻止這種疾病。”

一種可能性就是廣泛使用的抗癌藥物美羅華(Rituximab),已知該藥物殺死該病毒所隱藏的免疫系統細胞。如今,它正在用作治療多發性硬化症的臨床試驗中。

另一種可能性就是使用抗病毒治療,也將在Gavin Giovannoni教授和同事們當前準備的臨床試驗中接受測試。

Meier博士補充道,“如果我們能夠查明EBV是疾病引發者,我們就可能改變多發性硬化症的療程,甚至潛在地通過治療該病毒來阻止這種症狀。”

有意義的是,該研究也提示EBV感染和它在免疫系統上的作用可能也在諸如癌症和中風之類的其他大腦疾病中發揮作用。(生物谷:towersimper編譯)

Association of innate immune activati​​on with latent Epstein-Barr virus in active MS lesions

JS Tzartos, DPhil, G. Khan, PhD, A. Vossenkamper, MD, M. Cruz-Sadaba, PhD, S. Lonardi, MSc, E. Sefia, MSc, A. Meager, PhD, A. Elia, PhD, JM Middeldorp, PhD, M. Clemens, PhD, PJ Farrell, PhD, G. Giovannoni, PhD and U.-C. Meier, DPhil

Objective: To determine whether the activation of innate immune responses, which can be elicited by pathogenic and endogenous triggers, is associated with the presence of Epstein-Barr virus (EBV) infection in the multiple sclerosis (MS) brain. Methods: White matter postmortem MS (n = 10) and control tissue (n = 11) was analyzed for the expression of the proinflammatory cytokine interferon α (IFNα) by immunohistochemistry and for EBV by using the highly sensitive method of EBV-encoded RNA (EBER) in situ hybridization . Results: We detected overexpression of IFNα in active areas of white matter MS lesions but not in inactive MS lesions, normal-appearing white matter, or normal brains. The presence of IFNα in macrophages and microglia (expressing human leukocyte antigen class II) is suggestive of local production as part of an acute inflammatory process. Interestingly, EBERs were also specifically detected in areas where IFNα was overexpressed in these preselected active MS lesions. EBER+ cells were also found in CNS lymphoma and stroke cases, but were absent in other control brains. We next addressed a potential mechanism, eg, the role of EBERs in eliciting IFNα production, and transfected EBERs into human embryonic kidney (HEK) cells. We used HEK cells that stably expressed Toll-like receptor-3, which recognizes double- stranded RNAs, associated with many viral infections. EBERs elicited IFNα production in vitro. Conclusion: These findings suggest that latent EBV infection may contribute to the inflammatory milieu in active MS lesions by activating innate immune responses, eg, IFNα production. Unraveling the underlying mechanisms may help in uncovering causal pathways and developing better treatment strategies for MS and other neuroinflammatory diseases.

看完病毒篇,來看看血管篇吧!

第37屆世界介入放射性治療年會3/25在美國舊金山召開, 其中美國 Albany Medical Center in Albany, N.Y.的研究指出:

在4個月中,擴張靜脈,治療了213 個案. (72男性, 141女性; 平均年齡 49 歲) 其中包含了96 復發緩解型, 66 位 次要退化型 , 30位主要退化型. 多數症狀能夠消除

"復發緩解型中和主要退化型有大於75%的病人在肢體回復上有明顯的進展. 心理健康指數有70%進步. 次要退化型在肢體和心理健康指數進步比例有 59% 和 50%"

參考連結1,2,3

附上快速圖解 CCSVI 和MS的總整理說明連結 很棒 容易了解

https://www.facebook.com/notes/ccsvi-ivcc/critique-of-the-film-a-visual-lecture-of-multiple-sclerosis-and-ccsvi/313719305358792

還有下一個影片 把過去3年來對於CCSVI的總結做了一個最好的歸納整理

A Visual Lecture about Multiple Sclerosis and

CCSVI



Share/Bookmark

2012年3月2日 星期五

中樞神經靜脈循環異常CCSVI 三年來的觀察

此篇大致節錄翻譯自一位美國紐約MS病友 (自稱輪椅神風特攻隊)的文章

大意如下:
從我開始在這個部落格寫有關CCSVI的文章已經3年了,
剛開始時,只不過是在網路上由數十位病人在網路論壇上相互辯論這一個醫療發現.
直到今天, CCSVI的議題成為由患者在社會媒介所驅動的一個現象, 已經有2萬到3萬不等的MS病人進行了這一項醫療手術. 世界各地的研究人員都正對此議題如火如荼的研究著.
而這只是揭開神秘面紗的第一步.
上星期International Society for Neurovascular Disease (ISNVD)國際神經靜脈疾病學會在佛羅里達舉行,會中長達106頁論文集中有關於CCSVI的資訊被揭露, 連結在此 (click here)
其中,是給病人最感興趣報導包含幾個CCSVI治療醫生(頁62,79,83,84,86和87的PDF可以找到)顯示出多種治療效果,包含疲勞,認知的問題,熱敏感)而且RRMS(復發緩解型)患者比PPMS或SPMS患者復原更好。

下圖右側圓圈所指為血管窄化處

原文如下:

CCSVI: Three Years On, Some Thoughts and Observations

English: MRI image of a patient with CCSVI. Di...
Image via Wikipedia

It seems almost incredible, but it's been nearly 3 years since I wrote my first Wheelchair Kamikaze post on CCSVI (click here). At the time of that first post, CCSVI had hardly been heard of outside of some researchers in Italy and a few dozen patients debating the merits of the hypothesis on an Internet forum. Today, CCSVI has become a patient driven social media medical phenomenon. An estimated 20,000-30,000 patients have already undergone CCSVI treatment, researchers from around the world are investigating the hypothesis, and the surgical treatment of CCSVI has become a thriving industry. CCSVI has certainly come a long way, but in many ways we've only taken the first steps on what could be an epic journey.

Last week, the International Society for Neurovascular Disease (ISNVD) held its second annual scientific meeting, which lasted five full days, in Orlando, Florida. A tremendous amount of information about the nature and treatment of CCSVI was exchanged by researchers and physicians, a compendium of which can be found in a 106 page online PDF publication put out by the Society (click here).

Of most interest to patients are undoubtedly the treatment outcomes reported by several CCSVI treatment practitioners (which can be found on pages 62, 79, 83, 84, 86, and 87 of the PDF), which displayed a wide variety of treatment outcomes, but do seem to suggest several identifiable trends. It appears that quality of life issues (fatigue, cognitive issues, heat sensitivity) saw more benefit post treatment than mobility related issues, and that RRMS patients fared better than patients suffering from SPMS or PPMS. None of these studies was double blinded, all being observational and most relying on self-reported information, which can lead to inaccuracies. Still, the findings generally fall in line with some of the few double blinded studies that have been done, such as a recently completed study done in Italy (click here). CORRECTION:an anonymous reader points out that this Italian study was in fact not double blinded, and just used an independent physician to evaluate EDSS scores. Thanks for the heads up.

The meeting did bring into focus the fact that the CCSVI treatment protocol is far from standardized, with physicians varying in opinion on issues ranging from which veins to treat, whether treatment should concentrate on valves rather than the veins themselves, the use of intravascular ultrasound, and other important issues, a list of which can be found on pages 104-106 of the PDF document linked to above. There were quite a few presentations on the use of noninvasive imaging techniques (Doppler Ultrasound and MRV technology) to diagnose CCSVI, with the consensus appearing to be that neither method was especially accurate, except for extremely specialized MRV protocols that are practiced at only a few facilities. One leading CCSVI practitioner went so far as to state that he no longer requires his patients to undergo Doppler Ultrasound investigations before venoplasty, since the ultrasound results were found to be so prone to error (page 63 of the PDF).

In addition to presentations involving CCSVI treatment techniques, some important observations about the nature of the condition were also presented. The effects of reduced blood flow through the brain were discussed, as was the possible connection between bloodflow disruptions and a breakdown of the blood brain barrier, and the role of iron deposition in the MS disease process. In all, my impression (keeping in mind that I did not attend the meeting) is that the findings presented at this year's ISNVD scientific meeting were more evolutionary than revolutionary, which I suppose is something to be expected. The explosion of interest in CCSVI amongst interventional radiologists and research physicians must logically lead to attempts to fill in the many gaps of knowledge that remain in regards to CCSVI, before more dramatic leaps in understanding can be accomplished.

This eruption of interest in CCSVI within the interventional radiology community is in some ways a double-sided sword. On the plus side, it has given patients access to treatment, which in the early days was extremely hard to come by. Today, patients have their choice of treating physicians, and must do their due diligence when choosing which physician in whose hands to place themselves. As noted above, treatment techniques and philosophies vary widely from physician to physician, and patients exploring the possibility of CCSVI treatment should not be shy about asking questions in an effort to find a doctor whose treatment modality best fits their comfort level.

On the potentially negative side, CCSVI has become big business. With CCSVI treatment procedures costing about $10,000, and somewhere between 25,000-30,000 patients already treated, a little math reveals that treating CCSVI has already generated hundreds of millions of dollars in gross revenue for treating physicians. Yes, those procedures covered by medical insurance probably don't get reimbursed at the full rate charged, but this is likely made up for by patients who have undergone multiple procedures because of CCSVI's ongoing problems with restenosis. Given the fact that the number of treated patients represents only a tiny percentage of the worldwide MS population, it's easy to see that CCSVI treatment could quickly develop into a multibillion-dollar a year enterprise.

The David vs. Goliath narrative that has driven the CCSVI story thus far may soon become obsolete. To be sure, the neurology community still remains incomprehensibly steadfast in its negativity regarding CCSVI, but this is becoming counterbalanced by the enthusiasm of the interventional radiology community, and, I suspect, by the interests of the medical device manufacturers, who also stand to profit greatly should CCSVI become an accepted treatment option for MS patients. Despite the fact that very legitimate issues remain regarding the efficacy of CCSVI treatment and the lack of a consensus as to optimal interventional techniques, CCSVI treatment is being aggressively marketed by several US and international treatment facilities, which should raise some ethical questions.

Until issues with effectiveness and technique are satisfactorily answered, the CCSVI treatment procedure must be considered an experimental one, a fact that should not be lost on patients who are understandably desperate to address their illness but faced with a dizzying array of statistics, patient testimonials, and marketing efforts by for-profit ventures. In a very real way patients who choose to undergo CCSVI treatment at the current time are guinea pigs, a fact that I understood explicitly when I underwent my venoplasty back in the dark ages of CCSVI, almost two years ago. Although we've come a long way since then, in some ways the procedure remains as experimental as ever, as physicians treat a much wider array of veins much more aggressively than they did back when I underwent the procedure. Though the treatment is a minimally invasive one, it is not without risks, as is evidenced by the contingent of patients who have experienced clotting issues and vein thrombosis in the aftermath of their procedures. Indeed, one of the presentations at ISNVD highlighted a patient whose condition worsened after treatment (page 89 of the PDF), a rare occurrence to be sure, but a possibility that must factor into the decision-making process of patients considering venoplasty.

One of the most volatile controversies raging on CCSVI forums and social media sites is whether or not the condition is a cause or effect of multiple sclerosis, with those arguing for CCSVI as cause often citing the fact that the venous abnormalities being found appear to be congenital (developed in the womb) in nature. I am unsure as to the question of cause vs. effect, although I do believe that if CCSVI is a cause of MS, it is only one of many factors involved in the initiation of the disease. Even if the vascular defects being found in the veins of MS patients are congenital, this does not necessarily mean they are a cause of multiple sclerosis. There are many congenital defects that cause no adverse effect whatsoever, and I'd venture to say that many of us have some physical trait somewhere in our bodies that is outside of normal variance.

We've all heard stories of world-class athletes suddenly collapsing during or directly after extreme physical exertion. Quite often, the follow-up story is that the unfortunate athlete was a victim of a congenital heart defect, which would never have been noticed had that person not pushed his body to physical extremes. Had they not been athletes, they very well could have lived a normal life span. Likewise, a person born with congenitally abnormal ligaments in their knees might never know of their condition unless they encounter an environmental element (such as a hit to their knees) that brings their abnormality to the fore, in the form of a knee injury more severe than that which might have been suffered by a person with "normal" ligaments. Given the varied elements that have been linked to MS (infectious agents, exposure to toxins, vitamin deficiencies, genetic markers, etc.), a likely scenario is that vascular abnormalities play a part in predisposing an individual to developing MS when exposed to an unfortunate storm of other factors.

To my mind, it is becoming increasingly clear that, despite our greatest hopes, CCSVI is only a part of a much bigger and more complex MS picture. Precisely how big a part it plays is still open to question. Although CCSVI treatment does appear to benefit many patients, it has also been shown to be of little or no value to many others. CCSVI does not explain some of the factors that have previously been established about MS, such as the geographic distribution of the disease (click here), the male-female ratio that is well known to exist in MS (click here), the existence of "Multiple Sclerosis clusters" (which would seem to point to an infectious cause-click here), or the unmistakable link between MS and Epstein-Barr virus (click here). Nevertheless, CCSVI offers the promise of opening up whole new areas of research into the causes of, and treatments for, multiple sclerosis. Certainly, interested MS patients should investigate the possibility of CCSVI treatment, and make a sober assessment as to whether now is the proper time for them to jump in.

There are several ongoing research projects that should further illuminate the CCSVI picture scheduled to publish results later this year, but further robust and expeditious research is desperately needed. It is essential that we ascertain just how prevalent CCSVI is in the healthy population, gain a better understanding of the role, if any, of vascular abnormalities in the MS disease process, determine which MS patients respond best to CCSVI venoplasty, refine the techniques used to treat CCSVI, reduce the number of patients who experience restenosis, and see the development of surgical implements specifically designed to treat venous abnormalities. Neurologists need to get on board to provide interdisciplinary expertise to CCSVI studies. After all, whatever the results of the research, positive or negative, answering these questions can only be in the best interest of their patients.

CCSVI has come a long way, but there is still a long way to go. Ahankfully, the pace of CCSVI research is gaining momentum, and hopefully we will see answers to many of our questions sooner rather than later. In the meantime, my best advice is to educate yourself to the best of your ability, be your own most powerful advocate, and make treatment decisions based more on reason than emotion.

Share/Bookmark

2012年2月28日 星期二

新藥和醫療發展更新

新藥(諾華藥廠)Gilenya 口服藥物的回顧檢驗

Health Canada is reviewing a new multiple sclerosis drug that has been linked to 11 deaths.

加拿大衛生局正在檢視和Gilenya代號FTY720 (fingolimod) 口服藥物是否上市,因為此醫藥物目前造成11位MS患者的死亡

There have been no reports of deaths in Canada of people taking the Novartis drug, which is sold under the brand name Gilenya.

Gilenya, also called fingolimod, is taken once a day for people with the relapsing-remitting form of MS.Gilenya, also called fingolimod, is taken once a day for people with the relapsing-remitting form of MS. (Novartis)

Health Canada says that of the deaths outside the country, it's not clear whether the drug itself caused them, or whether other factors played a role.

Both the U.S. Food and Drug Administration and the European Medicines Agency had earlier announced that they were undertaking reviews of Gilenya.

包含美國FDA和歐洲藥品局早先都宣布再次檢視此藥物的情形

Gilenya is used for treatment of relapsing-remitting MS to reduce the frequency of attacks and to delay physical disability; it is generally recommended when other MS treatments have not been effective or cannot be tolerated.

At the time the drug was authorized, it was known that certain types of heart rhythm disturbances can be seen with Gilenya use and the Canadian labelling contains several warnings to this effect.

But Health Canada says it felt the drug's benefits outweighed its risks.

Of the 11 reported deaths, four involved serious heart-related events — three were heart attacks and another a disturbance of the heart rhythm. The seven other deaths are unexplained, including one from the United States involving a person who died within 24 hours of his or her first dose of Gilenya.

這11位死亡的案例中有4位和心臟相關 (3位心臟病1位心率不整) 其他7位未明(其中一位第一次服用後24小時內就死亡)

Health Canada says people taking the drug should not discontinue it without consulting their doctor. But anyone on the drug who is feeling symptoms of heart disease — including chest pain, slow or irregular heartbeat, or dizziness — should seek medical care.

The department says doctors should monitor patients on the drug closely. Blood pressure should be checked regularly as the drug is known to increase blood pressure.

看來目前只有Ampyra還較為安全(通用名稱dalfampridine,以前稱為fampridine),是第一個臨床治療是口服和第一個同類接受FDA的批准。其目的是幫助人們與任何類型的MS提高步行速度。該藥物的研製藥廠為 : Biogen Idec

更多閱讀:

美國FDA 批准第一個多發性硬化症的口服新藥

醫療發展更新

Application closes for MS Liberation treatment study in New York

日前有關於加拿大Saskatchewan和美國共同進行靜脈擴張術研究的申請名額已經額滿,加拿大共接到682患者参與實驗研究
For hundreds Multiple Sclerosis patients in Saskatchewan the next few months will be spent waiting.

On Friday, February 24 the deadline closed for the provincially funded MS Liberation Treatment trial in Albany, New York. The government received 682 applications to be part of the trial

Lori Lumax is one of the many people hoping to be chosen for the double-blind study and she is happy to see the government taking a step in the right direction.

“I’m really happy that this is going and there’s more studies coming out all the time so Canada is getting on top of it finally,” Lumax said.

The 46-year-old from Regina was diagnosed in 2003 and most of the time she only feels tired and dizzy. About once a year she has a relapse of symptoms which affect her cognitive functions causing her to lose feeling in her hands and feet and her balance.

Lumax said she is very excited for the study because all of the data will be documented to see if the controversial liberation treatment really works.

“If I’m not chosen for this trial – well, I’ll be looking at other trials coming up,” she said, explaining that she doesn’t want to wait for two years to see if the treatment will be offered here.

Lumax added that she is not willing to go overseas for treatment because she wants to know that there will be after-care in place.

Saskatchewan has one of the highest rates of MS with 3,500 people suffering from the disease. Starting in March the provincial government will send 86 patients to participate in the study in New York.
3月開始將會有86名Ms患者至紐約進行實驗手術研究


Share/Bookmark

2012年2月21日 星期二

我看 杰若米.林 J.L. update

除了杰若米.林 的故事之外,
請大家可以想想其他運動員的故事

王建民 一個連續兩年拿到19勝卻因為受了傷的投手,再站起來, 更能夠激勵人心
同樣的也要感謝國民對的老闆和教練

郭弘志 一個經歷過3次韌帶重建手術的選手, 能夠再站起來, 也是要感謝道奇隊的教練

面對旁人冷漠奇異的眼光, 以及現實冷酷的環境.

還有很多沒沒無聞, 或罕見疾病的小小英雄們, 他們也都能夠經歷人生最嚴苛的環境, 活出自己的生活.

你們就是身邊的杰若米!

Share/Bookmark

我看 杰若米.林 J.L.

從麥可喬丹(M.J.)退休後 直到杰若米.林 (J.L)出現後. 才重新喚醒曾經存在學生時代的血液.
也再度回想起2009年某一天我的心情
看到杰若米,就讓我想到研究所的一位朋友,
他也是籃球愛好者,我們以前常常聚在一起打球.

媒體大幅報導著這樣一個灰姑娘還有他背後所不為人知的故事.
在極端惡劣的環境中,到底該如何來面對,才是這個故事要告訴我們的.
雖然,不是每個人的際遇都能夠像杰若米一樣,遇到尼克隊的教練.



看著許多訪談,其中最讓我印象深刻的是:

不要讓旁人影響你,無須理會旁人對自己的言語或眼光
這一點尤其重要, 因為你是你, 旁人不是你. 旁人怎麼看你都不重要, 你不是為其他人而活.

家人有著共同的信念,緊密的結合,能夠相互支持和鼓勵.

信仰很重要,它是支持你繼續的一部分.


當他成為眾人目光焦點的時候, 才是真正考驗的開始,
隨之而來的將會是NBA最嚴酷的試鍊(骯髒的犯規...etc).
還有週遭給予的壓力(失去自我的隱私和生活),
甚至是名和利的誘惑


另外附上其他人一些對杰若米的體悟,瞧瞧囉.

名字縮寫也是J.L. 的我與有榮焉. May the force be with you, Jeremy.

Share/Bookmark

2012年2月6日 星期一

有沒有不經由手術就能夠讓靜脈狹窄的問題不再惡化的方式?

大家新年快樂,好久不見,祝大家龍年攏健康。

這篇篇名很長,也是我想要去找到的答案

或許有,但也許不是一朝見效。我想,國際上已經有很多的研究證據指出,中樞靜脈循環不全會造成肢障或是加重MS的症狀。而氣球擴張術也已經證實了是一項足夠安全而且是解決最快的方式。
我們是多麼幸運,能夠有這樣突破性的進展,來幫助我們。

遺憾的是:可能會再窄回來。
支架,是一個能夠延長窄化時間的方式,也毋庸置疑。
但,能夠延長多久呢?

記得之前,北榮的胡醫師在他的臨床檢驗當中發現了用力呼氣能夠增加內頸靜脈內些許的血流量。
不久之前,在我住所附近的醫院中也有一位神經內科醫師:蘇醫師,在知道了我的過去的病史和義大利桑伯尼醫師的論文之後,並不會對這一個新的理論排斥或表示否定的看法。
反而,他教我一個呼吸的方式,(他用科學的角度來說明)讓我覺得有機會去打通轉折處可能阻塞的問題。

蘇:你以前是不是常閉氣?
我:游泳的時候
蘇:最好不要常常閉氣,而且不要吸飽氣之後閉氣,因為吸飽氣之後閉氣會造成胸腔的壓力增大,相對於腦部的血液可能會流不下來。而吐氣要吐到盡,盡可能的把所有的氣都吐出來,讓胸腔變小,造成胸腔的壓力變低,腦部的血液可能會因為壓力差而往下流。記得,吐盡氣後,閉氣再將腹部挺出,讓橫隔膜下降,讓肺部空間變大,造成胸腔壓力變小(類真空狀態)。造成壓力差,有機會讓腦血液往下流,你試試看。

在說完之後,我就立刻做了一次,我的感覺是:
在吐盡氣後,閉氣,腹部挺出之後沒多久(約5-8秒),麻麻的感覺由頭頂慢慢的往下,經過我的咽喉,到胸腔。
當下,很興奮,雖然我不知道麻的感覺是不是代表著血流,但是,很特別。

但是,不是每一次都有相同的感覺,也許是我阻塞的太過嚴重了吧。

這是一個很神奇的經驗,分享給大家,讓大家也試試看。
我後來發現,吸氣的時候,會有由胸腔往頭頂上麻的感覺,你們也可以試試看。

附上圖,讓大家試試看

註:請參考我網誌2011/7/23的文章

頸靜脈之自我擴張IJV Self-expasion

Keep breathing!
Share/Bookmark

2012年1月18日 星期三

因為肢體肌肉張力太而困擾嗎?

治療肢體肌肉痙攣的方法很多,各種治療方式可互相搭配使用,例如以口服藥物無法改善的痙攣,則可改用肉毒桿菌素注射;但無論如何都不能忽略持續復健的重要。

為什麼會發生肢體痙攣?

台北榮總復健科醫師周正亮指出,肢體動作由腦細胞控制,當腦細胞受傷或壞死如中風,就可能使運動神經元過度興奮,導致肢體張力太強,而使肌肉緊繃及痙攣或肌力不足,而無法支撐動作。

台北醫學大學附設醫院副院長、復健部主任陳適卿則指出,不只中風後可能發生肢體肌肉痙攣的後遺症,其他如頭部外傷、脊髓損傷、多發性硬化症、腦性麻痺等,也都可能產生這樣的後遺症。

治療方法多,各有優缺點,可相輔相成

陳適卿指出,目前治療肢體肌肉痙攣的方法很多,在選擇治療方式之前,要先考慮痙攣嚴重程度、要不要使用侵入式治療、要全身或局部性效果、可逆或不可逆、價格 如何等。各種治療方式可互相搭配使用,例如以口服藥物無法改善的痙攣,則可輔以肉毒桿菌素注射;而以肉毒桿菌素注射治療的患者,更不能忽略持續復健的重要。

注射肉毒桿菌素,仍要積極復健

陳 適卿表示,並不是所有中風後產生肢體肌肉痙攣的人,都需用肉毒桿菌素來治療,例如痙攣不嚴重、也不致於有關節變形疑慮的患者,或許只要擺位正確即可改善。 但若因痙攣太嚴重、肌肉張力太強,已明顯影響日常生活的動作(例如手掌無法張開拿東西、手無法舉高更衣、足內翻而無法練習行走甚至跌倒等)、或影響到清潔 衛生(例如肌肉張力太大,肢體攣縮而難以清潔)、肌肉痙攣縮導致關節可能變形,或肌肉張力過大,而引起疼痛不適、甚至晚上睡不好等,都可考慮使用肉毒桿菌 素來改善。

他 表示,通常使用肉毒桿素對肌肉痙攣的改善效果很好,患者肌肉放鬆不再痙攣,所以可抓東西、清潔,也不再因足內翻而容易扭傷或跌倒、不再疼痛。但陳適卿強 調,對肉毒桿菌素也不要有過度期待,不但使用前要評估適當的患者,使用效果才會更好,且注射肉毒桿菌素後的持續復健非常重要,才能使中風後的動作功能逐漸 進步。

周 正亮也表示,注射肉毒桿菌素會使肌肉張力下降,所以必須是患者本身有自主控制能力(以免原本因肌肉張力作用而能站立的患者,肌肉張力減弱後反而癱軟無力 了)、且肌肉張力太強以致於影響了日常生活功能時,才適合使用;最重要的是肉毒桿菌素注射只是復健的一部分,注射後的復健仍要積極進行,因肉毒桿菌素就是 要使復健更容易進行、對日常生活功能的改善才會更明顯。

他 說,為了讓中風後肢體肌肉痙攣患者有最好的治療方式,常要做多方面的綜合評估與治療建議,而肉毒桿菌素則是積極治療很好的輔助方法,若能讓只能坐輪椅的患 者因此得以復健、而能站起來走路,或讓原本手掌無法張開拿筷子,或能拿叉子取食物卻無法靠近嘴巴、無法洗臉的患者得以改善,對生理、心理都會是很好的正向支持。


案例:
中風後的陳伯伯,右半身 癱瘓,行動變得非常不便,不但右腳足內翻而影響行走,緊緊握拳的右手掌也幾乎無法張開,醫師說這是中風引起的肢體肌肉痙攣;但陳伯伯努力復健了半年,肢體 動作卻似乎沒什麼起色,那緊緊握拳、難以張開的右手掌,除了妨礙手部動作,影響姿態觀瞻,也造成清潔衛生上的不方便。

陳伯伯在各種復健仍無法 改善肌力痙攣問題後,在醫師建議下接受肉毒桿菌注射,並持續復健。由於肌肉張力降低,陳伯伯緊握拳的右手掌得以張開,不但指甲不會再因用力握拳而刺入手掌 心裡,更可以好好的洗手、不再傳出臭味,也可開始抓取物品的復健練習;而右腳不再因張力過大而足內翻,終於可以站穩、努力復健、慢慢學著往前走了。

是否要注射,還請大家針對自己的情況,並且尋求該文章所提的兩位或其他專業的醫師們尋求詳細的諮詢,做出適合自己的判斷。

附上原文連結:
http://tw.myblog.yahoo.com/jw!7WgQOmmfSE9K9hUsAfA-/article?mid=1798
Share/Bookmark

2012年1月15日 星期日

缺氧CCSVI與抑鬱症

國外有一位病友提到了憂鬱和缺氧的關係,而慢性腦脊髓靜脈循環障礙 CCSVI也是缺氧的主要原因之一

若有慢性缺氧的情形會比較容易發展抑鬱症。

血氧正常水平的95%至100%之間波動,任何正常的成人。吸煙者可以徘徊在92%。
看到這裡,誠心的奉勸吸煙的朋友,吸煙無疑的讓自己缺氧,而之前西方外國的研究也指出,抽煙得MS的比例也比較多。若是你已經得了MS,再加上又有靜脈血管窄化的問題的話,請你一定要戒菸。
任何人的血氧含量若小於 85%至90%,你就需要戴上氧氣面罩。
在腦缺氧,有時只有氧氣供應中斷。這可能是由於:
1.在火災煙霧吸入濃煙
2.一氧化碳中毒
3.慢性腦脊髓靜脈瓣膜功能不全(CCSVI)
4.窒息
5.防止呼吸肌的運動(麻痺)的疾病導致,如肌萎縮性側索硬化症(ALS)
6.在高海拔地區
7.壓力(壓縮)氣管(氣管)

在其他情況下,氧氣和營養供應停止,所造成的:
1.心臟驟停(時心臟停止抽水)
2.心律失常
3.全身麻醉的並發症
4.溺死
5.藥物過量
6.中風
7.非常低的血壓(低血壓)
腦細胞缺乏氧氣極為敏感。一些腦細胞開始死亡不到5分鐘後,他們的氧氣供應消失。因此,大腦缺氧,可迅速導致嚴重的腦損傷或死亡。包含下列症狀:

注意的變化(不專注)
判斷力差
不協調的運動

慢性缺氧,臨床抑鬱症包含下列症狀:

坐立不安
焦慮
神誌不清,
混亂,
疲倦
無精打采
頭痛
混亂
短期記憶喪失
持續的身心疲勞
低迷的心理反應
喪失執行物理任務的能力
肺動脈高壓(PH)
右心衰竭
紅細胞增多症(高紅細胞計數)
干擾內皮源性一氧化氮依賴性血管舒張功能
心動過速(心跳率增加,每分鐘超過 100)

Share/Bookmark

2011年12月23日 星期五

再論腸阻塞/腸沾黏

之前我有一篇文章

MS病友要注意的事:體重下降

曾談到

腸沾黏是許多經歷過腹部手術患者的難言之隱。
腹痛、腹脹、嘔吐、便結等症狀,常使得患者萌生「不如不開刀」之感。

先天性的腸沾黏多為發育異常,或由胎糞性腹膜炎所引起,臨床上並不多見;
現代腸沾黏的主要原因為腹部手術、腹膜炎、創傷或腫瘤所引起。
由於以上多種原因造成原本無菌狀態的腹膜發炎,
繼發纖維蛋白性的黏連,把腸壁與鄰近組織癒合成一塊,
造成蠕動困難,就像被厚重的蜘蛛網纏住一樣,於是造成了腸沾黏。

腸沾黏的第一個症狀就是腹痛,尤其以肚臍周圍的腹痛最多,
伴隨著脹氣,常使患者失去工作能力及意願。
若沾黏部位較高,還可能伴隨著嘔吐食物或胃液,並且可能造成排便或排氣停止。
以上是 腸沾黏

首先呢…可以吃維他命B群,特別是維他命B1能促進腸道的蠕動。
適量的運動和愉悅的心情都可以幫助腸道的蠕動。
高纖維飲食還有一個要注意的問題就是維生素與礦物質的補充,
所以建議您可以在早餐飯後再補充一顆綜合維他命。
在飲食上,建議或許可以吃清淡飲食、減少脹氣;
目前也有研究認為,乳酸菌有促進腸蠕動的效果,可能幫助改善。
偶而作一些輕鬆的運動,如散步,打太極拳等也有助於促進腸胃之蠕動。



有病友會問:那我都走不了了,還散步?打太極拳?
那我再提供給各位一個也曾經做過血管擴張術病友提供的很好的建議:平甩功
他做了之後,更幫助他的腳活動能力。
我在聽了他的建議之後,也持續做了一個多月之久,我發現不論坐著或站著,在做至少半小時以上之後會促進放屁和排氣。

附上平甩功的參考




而中醫治療腸沾黏以「通」為原則,
發作期治療以通裡攻下為主,
兼以理氣開鬱、活血清熱為輔,在緩解期注意綜合調理,
使脾胃強健,預防復發,並根據病情發展,必要時,應轉手術治療。

可以用熱水淋浴肚臍周圍,再用手掌依右下→右上→左上→左下的順序用力按壓腹部。
按壓的深部大約是3至5公分。沾黏嚴重的患者常可以觸摸到一團團成塊狀的硬物,
會有些許的疼痛感
。雖然可以在家進行居家護理,但當嚴重發作時,還是要請醫師處理,
否則經常性的便秘,有誘發大腸癌的可能。

中醫治療:

發作期的治療
●氣滯腑實:腹痛陣作,叩之有鼓音。腹痛時,腹部可見條索狀物隆起,伴隨噁心、嘔吐,治宜行氣通下,以硝菔通結湯加減大腹皮、姜半夏、桔梗主之。
●熱結腸腑:腹痛拒按、腹脹痞滿、發熱、口乾、唇燥、小便短赤,治宜瀉熱通下,以大承氣湯加減金銀花、蒲公英以清熱解毒。
●寒結腸腑:腹中突然絞痛,脘腹怕冷,腹脹便秘,面色青暗,治宜溫中通下,宜溫脾湯加減吳茱萸、細辛等,以溫陽散寒。
●腸腑血瘀:腹痛重於腹脹,痛有定處,脹無休止,局部拒按,可觸及痛處包塊,治宜祛瘀通下,以桃仁承氣湯加減田七、川芎。

☆緩解期的調養
●脾虛氣滯:腹陣痛時作,氣短乏力,大便不暢,治宜健脾行氣,方以陳夏六君子湯,加以火麻仁,重用黃耆以補氣潤腸。
●津虧腸燥:大便乾結、經常便秘、腹痛時作,治宜潤腸通便,以五仁湯加味。桃仁、柏子仁、郁李仁、瓜蔞仁、火麻仁為多汁潤腸之品,加以厚朴行氣調血,合奏潤腸通便功。氣陽不足者加太子參、麥冬,以益氣養陰。
平常可用艾灸足三里、內關、合谷穴,以達到健脾理中的效果。天樞、氣海、關元穴等,在這些穴位下針灸,即可針對剖腹產所產生的腸沾黏以及脹氣或便秘有所改善。


豐原醫院營養師鄭秀英表示,曾發生腸子沾黏導致腸阻塞或腸胃道功能欠佳的中老年人,飲食應採低刺激性、低渣,以減少阻塞發生,
更應避免食用油炸類、 奶製品、全穀類製品、堅果類、過於油膩食物及辛辣、刺激性的調味品,蔬菜應攝取葉的部份,避免根莖部,不宜同時段吃下大量高纖維食物。最近盛產甜柿,鄭秀英提醒老年人或腸胃道消化功能不好的人,不宜一次大量食用,飲食也需保持定時定量、細嚼慢嚥,避免引發腸阻塞。多喝水。
低渣飲食,例如過濾過的果汁,及補充電解質,避免吃產氣食物易引起脹氣,忌食牛奶及奶製品。


更多閱讀:其他由Google得到的參考資料
Share/Bookmark

2011年12月18日 星期日

續 : 另類療法外一章:施予,給予

承前 :

然後,針對她的症狀,卡蜜從一位朋友那裡得到一帖處方。這位朋友是個名叫安芭莉.克里佐的南非藥婆──這帖處方是要在二十九天送出二十九件禮物。

  安芭莉告訴她:「透過給予,妳會把焦點放在妳所擁有的、妳能提供給他人的東西上,進而讓妳的人生更豐足。」她又說:所謂的禮物可以是任何東西,重點在於妳的給予是真誠而有心的。這當中,至少有一件禮物必須是卡蜜認為自己的人生相當缺乏的東西。

  這趟為期二十九天的旅程讓卡蜜眼界大開、驚歎不已。

所感 :

從罕病天使楊玉欣所主持的角落欣世界第181集中的訪談內容當中有這麼一段:『要幫助別人必先看見他們的需要,而們真正 的需要再哪?這就需要一定程度的理解。然後還要突破各式各樣的困難,必須要用心,要貼心的去完成這一份使命。』當集來賓 張煒青(現任台新銀行客戶關係管理處處長)說道:『以前我對公益的瞭解就是我捐一些錢,逢年過節的時候,把多餘的玩具衣物捐出來,但是後來在我親自從事這 個台新公益慈善基金會活動的時候,接觸到很多的社福團體,我才知道只是把金錢捐出去幫助其實是最小的。真正的幫助是把你的心力投入到這些需要被幫助的人, 而不是說只把一些身外之物捐出來而已。最重要的地方在於要瞭解他們的需要,然後用我們實際的力量,真正落實到解決他們的需要,這樣才算真正幫助到他們。』 就像一句話所說的:送禮要送到人家心坎裡。就是這個意思吧。

回顧我患病之前,我助人的方式也只不過如張煒青處長所說的那個樣子。坦白說,捐完錢之後,心中真的沒有很愉悅的快樂或者是嘴角微微揚起的愉悅感。反 而是患病之後的日子才真正的體會到了助人為快樂之本的真諦,因為我親身經歷,我感同身受,我知道他們真正的需求。不用金錢,選擇用文字真切的表達出內心的 轉折,激勵同是受到病痛打擊的病友,提供另一種形式心靈上的慰藉,提供病友們最新的醫療訊息,又何嘗不是一 種切入人心的幫助?套一句我研究所指導教授所說:『與其給你一條魚,不如給你一個釣竿?』

ThanksGiving 感恩給予

當收到禮物的時候, 不論是否喜歡, 請感恩送禮人的那份心, 那份情, 那份愛......



Share/Bookmark

2011年12月5日 星期一

另類療法外一章:施予,給予


我昨天看到了這一本書,在這之前,我已經耳聞這樣的新聞,到昨天才見其真面目。

這是一個真實的故事,

書中的作者卡蜜婚禮過後一個月,二○○六年診斷出多發性硬化症,兩年後在網路上發起了二十九天送禮大挑戰。從那時起,她不曾間斷地持續著送禮二十九天的循環。,三十三歲的卡蜜.沃克被診斷出多發性硬化症,她的人生從此再也不同。不多久,卡蜜就在洛杉磯各醫院的急診室進進出出,頻率高到令人警覺 事態嚴重的地步。在此同時,她力搏害得她幾乎無法走路又讓她的婚姻承受無比壓力的神經病理症狀。每一天都為她帶來新的負面思維:我最後會落得坐輪椅、丈夫 會離開我吧、我的人生完了、這種事為什麼要發生在我身上……

然後,針對她的症狀,卡蜜從一位朋友那裡得到一帖處方。這位朋友是個名叫安芭莉.克里佐的南非藥婆──這帖處方是要在二十九天送出二十九件禮物。

  安芭莉告訴她:「透過給予,妳會把焦點放在妳所擁有的、妳能提供給他人的東西上,進而讓妳的人生更豐足。」她又說:所謂的禮物可以是任何東西,重點在於妳的給予是真誠而有心的。這當中,至少有一件禮物必須是卡蜜認為自己的人生相當缺乏的東西。

  這趟為期二十九天的旅程讓卡蜜眼界大開、驚歎不已。

   本書深刻記錄卡蜜這二十九天的難忘故事,她張開雙臂擁抱給予與接受的自然過程,許多她所送出的禮物都很簡單──一通電話、多餘的零錢,甚至只是一張面 紙。然而,這些善意的舉動具有改變的力量。到了第二十九天,她不只變得健康、快樂,還著手發起一個廣及全世界的付出運動。

  本書也收錄來自二十九件禮物官方網站線上社群成員的文章,他們的人生在參與二十九件禮物大挑戰後越變越好。本書讓你看到簡單但每天持之以恆的利他行為可以如何讓你對這世界的觀感從根本上改變。

  聽起來不可思議,有時候能最有效解決自身的問題,就是開始去傾聽他人。
  這是一個真實故事,給予力量之大,所回收的超出想像。

禮物其實不一定是實體的禮物。可以是一份關心、一份心意,一句問候。在付出、與思考如何付出的過程中,我們看待世界的眼光不同了,價值觀與視野也不同了。而這種付出,是不求回報的付出。因為禮物是要送給他人的。送出去當然不求回報。哪有送出去還求回報的禮物呢?

自己或許也就像書中主角一樣,只不過想著資訊的分享,但無形當中自己也因此獲得極大的快樂。

真的能夠治病嗎?能夠痊癒嗎?

卡蜜於後記中提到:「我希望我能說送出二十九件物治癒了我的多發性硬化症,但事實並非如此。我仍舊承受著此一疾病帶來的衝擊… …。」她只想告訴大家,藉著送出29個禮物,為她及周遭親友帶來轉變。

雖然不能夠治癒,但是在這過程當中,他享受到了無限的快樂和幸福。
就像一部印度片:3個傻瓜中的一句話:相信All is well就能夠解決問題嗎? 並不會,但是這讓我們不再害怕!

施比受更幸福,施比受更快樂。(不求回報的...)Remember, Thanks giving! 也請感恩。

更多閱讀:
3個傻瓜http://blog.udn.com/tintin2/5057160
All is well

29個禮物網站:http://www.29gifts.org/
Share/Bookmark